DLVR Therapeutics is focused on creating a unique nanoparticle delivery system that specifically targets lipophilic small molecules and siRNA to cancer cells. The company has two main programs: one aims to enhance the safety and efficacy of existing chemotherapeutic drugs, while the other focuses on targeted siRNA delivery. DLVR is actively seeking collaborations with biopharmaceutical partners for both programs.